{"id":113,"date":"2023-01-02T14:43:36","date_gmt":"2023-01-02T14:43:36","guid":{"rendered":"https:\/\/blog.ki.se\/nvsprefekt\/?p=113"},"modified":"2023-01-02T14:43:37","modified_gmt":"2023-01-02T14:43:37","slug":"det-ar-vart-det","status":"publish","type":"post","link":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/","title":{"rendered":"Det \u00e4r v\u00e4rt det!"},"content":{"rendered":"\n

English version below<\/em><\/p>\n\n\n\n

Ett nytt l\u00e4kemedel f\u00f6r behandling av Alzheimers sjukdom \u00e4r p\u00e5 v\u00e4g ut p\u00e5 marknaden. Det \u00e4r mycket efterl\u00e4ngtat. Allt b\u00f6rjade med en uppt\u00e4ckt som professor Lars Lannfeldt och hans forskargrupp, d\u00e5 med laboratorier vid KI och Novum, gjorde n\u00e4r dom analyserade en speciell form av amyloid-\u0392 peptid (A\u0392).  A\u0392 \u00e4r en del (=peptid) som klipps ut fr\u00e5n ett st\u00f6rre protein och bildar amyloida plack i hj\u00e4rnan, vilket tros leda till Alzheimers sjukdom. Det visade sig att detta speciella A\u0392 (med den arktiska mutationen) klibbade ihop p\u00e5 ett annat s\u00e4tt \u00e4n vanligt A\u0392 och forskargruppen tog fram antikroppar som binder till denna speciella form av A\u0392. Och p\u00e5 den v\u00e4gen \u00e4r det. Nu 25 \u00e5r senare och efter mycket entr\u00e4get arbete b\u00e5de inom akademin och industrin \u00e4r allts\u00e5 ett nytt l\u00e4kemedel p\u00e5 v\u00e4g att godk\u00e4nnas av FDA*. Det heter \u00e4n s\u00e5 l\u00e4nge Lecanemab och \u00e4r en antikropp som kan ges i tidiga stadier av Alzheimers sjukdom, det tar bort placken och bromsar ner f\u00f6rs\u00e4mringen av kognitionen. Det \u00e4r inte s\u00e5 att patienten blir helt frisk igen, men sjukdomsf\u00f6rloppet \u00e4ndras. Vi som forskar inom f\u00e4ltet, patienter och anh\u00f6riga fylls med hopp om att det g\u00e5r att p\u00e5verka sjukdomen. Det finns bieffekter som med alla l\u00e4kemedel och vi kommer att beh\u00f6va diagnostisera och unders\u00f6ka patienterna noggrant innan dom kan f\u00e5 l\u00e4kemedlet. Vi kommer ocks\u00e5 att beh\u00f6va ta fram andra typer av l\u00e4kemedel som till exempel p\u00e5verkar inflammation, autofagi, och mitokondriefunktion och som kan ges i kombination med antikroppar mot amyloida plack f\u00f6r att kunna p\u00e5verka sjukdomens olika stadier. Faktum \u00e4r att ca 75% av de l\u00e4kemedelskandidater som nu \u00e4r ute i klinisk pr\u00f6vning riktar sig mot andra molekyler \u00e4n A\u0392\/amyloida plack och tau (ett protein som bildar nystan i nervcellerna).<\/p>\n\n\n\n

Jag var i San Francisco i slutet p\u00e5 november p\u00e5 konferensen d\u00e4r resultaten fr\u00e5n den stora fas 3-studien med Lecanemab presenterades. Man kunde ta p\u00e5 st\u00e4mningen i den stora salen d\u00e4r upp\u00e5t 2000 personer sp\u00e4nt lyssnade till resultaten. S\u00e5 m\u00e5nga g\u00e5nger har vi h\u00f6rt negativa nyheter fr\u00e5n olika kliniska pr\u00f6vningar, men nu: det ser bra ut! S\u00e5 hatten av f\u00f6r Lars Lannfeldt och hans kollegor vid KI, Uppsala universitet och det f\u00f6retag han startat. Ni visar att det \u00e4r v\u00e4rt det! Det \u00e4r v\u00e4rt att tro p\u00e5 sin id\u00e9, forska fokuserat, satsa allt, samarbeta och inte ge upp.<\/p>\n\n\n\n

NVS har bedrivit forskning om Alzheimers sjukdom sedan 1980-talet d\u00e5 professor Bengt Winblad kom till Huddinge sjukhus och b\u00f6rjade bygga upp den geriatriska kliniken parallellt med klinisk och experimentell forskning. Bredden p\u00e5 denna forskning \u00e4r imponerande och omfattar fr\u00e5gest\u00e4llningar runt till exempel omv\u00e5rdnad, tekniska hj\u00e4lpmedel, epidemiologi, prevention, diagnostik, cellul\u00e4ra mekanismer, m\u00e5lmolekyler och l\u00e4kemedelskandidater. Alzheimerforskarna vid KI samlas under Centrum f\u00f6r Alzheimerforskning (CAR) som har sin hemvist vid NVS. H\u00e4r ordnas bland annat seminarier och nationella m\u00f6ten vilket skapar m\u00f6jligheter f\u00f6r nya forskningssamarbeten.<\/p>\n\n\n\n

Att Sverige har en ledande roll internationellt inom Alzheimerforskningen m\u00e4rktes tydligt p\u00e5 konferensen i november, d\u00e4r tv\u00e5 av fyra Keynote-speakers kom fr\u00e5n Sverige. V\u00e5ra kollegor i G\u00f6teborg och Lund \u00e4r v\u00e4rldsledande inom biokemiska biomark\u00f6rer. Det som \u00e4r unikt f\u00f6r KI \u00e4r kunskap om prevention, hj\u00e4rnavbildning och bakomliggande cellul\u00e4ra mekanismer. Vi \u00e4r bra och kan bli \u00e4nnu b\u00e4ttre. \u00c5terigen: tro p\u00e5 din id\u00e9, arbeta fokuserat och samarbeta strategiskt.<\/p>\n\n\n\n

Det \u00e4r v\u00e4rt det!<\/p>\n\n\n\n

*FDA=U.S. Food and Drug Administration (USA:s livsmedels-och l\u00e4kemedelsmyndighet)<\/em><\/p>\n\n\n\n

It’s worth it!<\/strong><\/h1>\n\n\n\n

A new drug for the treatment of Alzheimer’s disease is on its way to the market. It is long awaited. It all started with a discovery that Professor Lars Lannfeldt and his research group, then with laboratories at KI and Novum, made when they analyzed a special form of amyloid-\u0392 peptide (A\u0392). A\u0392 is a part (=peptide) that is cut out of a larger protein and forms amyloid plaques in the brain, which is believed to lead to Alzheimer’s disease. It turned out that this special A\u0392 (with the Arctic mutation) stuck together in a different way than normal A\u0392 and the research team developed antibodies that bind to this special form of A\u0392. And on that road, it is. Now 25 years later and after very persistent work both in academia and industry, a new drug is on its way to being approved by the FDA*. It is so far called Lecanemab and is an antibody that can be given in the early stages of Alzheimer’s disease, it removes the plaques and slows down the deterioration of cognition. It is not the case that the patient becomes completely healthy again, but the course of the disease changes. We who do research in the field, patients and relatives are filled with hope that it is possible to influence the disease. There are side effects as with all medicines and we will need to diagnose and examine the patients carefully before they can receive the medicine. We will also need to develop other types of drugs that, for example, affect inflammation, autophagy, and mitochondrial function and that can be given in combination with antibodies against amyloid plaques to be able to affect the various stages of the disease. The fact is that about 75% of the drug candidates that are now in clinical trials target other molecules than A\u0392\/amyloid plaques and tau (a protein that form tangles in nerve cells).<\/p>\n\n\n\n

I was in San Francisco at the end of November at the conference where the results of the large phase 3 study with Lecanemab were presented. You could feel the atmosphere in the large hall where upwards of 2,000 people listened intently to the results. So many times, we have heard negative news from various clinical trials, but now: it looks good! Hats off to Lars Lannfeldt and his colleagues at KI, Uppsala University, and the company he started. You show it’s worth it! It is worth believing in your idea, doing focused research, betting everything, collaborating and not giving up.<\/p>\n\n\n\n

NVS has conducted research on Alzheimer’s disease since the 1980s, when Professor Bengt Winblad came to Huddinge Hospital and began to build up the geriatric clinic in parallel with clinical and experimental research. The breadth of this research is impressive and covers issues around, for example, nursing, technical aids, epidemiology, prevention, diagnostics, cellular mechanisms, target molecules and drug candidates. The Alzheimer researchers at KI gather under the Center for Alzheimer Research (CAR), which is based at NVS. Among other things, seminars and national meetings are organized here, which creates opportunities for new research collaborations.<\/p>\n\n\n\n

That Sweden has a leading role internationally in Alzheimer’s research was clearly seen at the conference in November, where two out of four Keynote speakers came from Sweden. Our colleagues in Gothenburg and Lund are world leaders in biochemical biomarkers. What is unique to KI is knowledge of prevention, brain imaging and underlying cellular mechanisms. We are good and can be even better. Again: believe in your idea, work focused and collaborate strategically.<\/p>\n\n\n\n

It’s worth it!<\/p>\n\n\n\n

*FDA=U.S. Food and Drug Administration<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

English version below Ett nytt l\u00e4kemedel f\u00f6r behandling av Alzheimers sjukdom \u00e4r p\u00e5 v\u00e4g ut p\u00e5 marknaden. Det \u00e4r mycket efterl\u00e4ngtat. Allt b\u00f6rjade med en uppt\u00e4ckt som professor Lars Lannfeldt […]<\/p>\n","protected":false},"author":474,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-113","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nDet \u00e4r v\u00e4rt det! - The NVS Head of department blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Det \u00e4r v\u00e4rt det! - The NVS Head of department blog\" \/>\n<meta property=\"og:description\" content=\"English version below Ett nytt l\u00e4kemedel f\u00f6r behandling av Alzheimers sjukdom \u00e4r p\u00e5 v\u00e4g ut p\u00e5 marknaden. Det \u00e4r mycket efterl\u00e4ngtat. Allt b\u00f6rjade med en uppt\u00e4ckt som professor Lars Lannfeldt […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/\" \/>\n<meta property=\"og:site_name\" content=\"The NVS Head of department blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-02T14:43:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-02T14:43:37+00:00\" \/>\n<meta name=\"author\" content=\"nvsprefekt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nvsprefekt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/\"},\"author\":{\"name\":\"nvsprefekt\",\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/#\\\/schema\\\/person\\\/aa04a4e5b947f775d2eb0f1724cb0da8\"},\"headline\":\"Det \u00e4r v\u00e4rt det!\",\"datePublished\":\"2023-01-02T14:43:36+00:00\",\"dateModified\":\"2023-01-02T14:43:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/\"},\"wordCount\":1238,\"commentCount\":0,\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/\",\"url\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/\",\"name\":\"Det \u00e4r v\u00e4rt det! - The NVS Head of department blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/#website\"},\"datePublished\":\"2023-01-02T14:43:36+00:00\",\"dateModified\":\"2023-01-02T14:43:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/#\\\/schema\\\/person\\\/aa04a4e5b947f775d2eb0f1724cb0da8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/2023\\\/01\\\/02\\\/det-ar-vart-det\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Det \u00e4r v\u00e4rt det!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/#website\",\"url\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/\",\"name\":\"The NVS Head of department blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/#\\\/schema\\\/person\\\/aa04a4e5b947f775d2eb0f1724cb0da8\",\"name\":\"nvsprefekt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cac143d503ca7ff40f299c87a89d200149e86c68819516e19e3937c32ce182e7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cac143d503ca7ff40f299c87a89d200149e86c68819516e19e3937c32ce182e7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cac143d503ca7ff40f299c87a89d200149e86c68819516e19e3937c32ce182e7?s=96&d=mm&r=g\",\"caption\":\"nvsprefekt\"},\"url\":\"https:\\\/\\\/blog.ki.se\\\/nvsprefekt\\\/author\\\/nvsprefekt\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Det \u00e4r v\u00e4rt det! - The NVS Head of department blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/","og_locale":"en_US","og_type":"article","og_title":"Det \u00e4r v\u00e4rt det! - The NVS Head of department blog","og_description":"English version below Ett nytt l\u00e4kemedel f\u00f6r behandling av Alzheimers sjukdom \u00e4r p\u00e5 v\u00e4g ut p\u00e5 marknaden. Det \u00e4r mycket efterl\u00e4ngtat. Allt b\u00f6rjade med en uppt\u00e4ckt som professor Lars Lannfeldt […]","og_url":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/","og_site_name":"The NVS Head of department blog","article_published_time":"2023-01-02T14:43:36+00:00","article_modified_time":"2023-01-02T14:43:37+00:00","author":"nvsprefekt","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nvsprefekt","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/#article","isPartOf":{"@id":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/"},"author":{"name":"nvsprefekt","@id":"https:\/\/blog.ki.se\/nvsprefekt\/#\/schema\/person\/aa04a4e5b947f775d2eb0f1724cb0da8"},"headline":"Det \u00e4r v\u00e4rt det!","datePublished":"2023-01-02T14:43:36+00:00","dateModified":"2023-01-02T14:43:37+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/"},"wordCount":1238,"commentCount":0,"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/","url":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/","name":"Det \u00e4r v\u00e4rt det! - The NVS Head of department blog","isPartOf":{"@id":"https:\/\/blog.ki.se\/nvsprefekt\/#website"},"datePublished":"2023-01-02T14:43:36+00:00","dateModified":"2023-01-02T14:43:37+00:00","author":{"@id":"https:\/\/blog.ki.se\/nvsprefekt\/#\/schema\/person\/aa04a4e5b947f775d2eb0f1724cb0da8"},"breadcrumb":{"@id":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.ki.se\/nvsprefekt\/2023\/01\/02\/det-ar-vart-det\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.ki.se\/nvsprefekt\/"},{"@type":"ListItem","position":2,"name":"Det \u00e4r v\u00e4rt det!"}]},{"@type":"WebSite","@id":"https:\/\/blog.ki.se\/nvsprefekt\/#website","url":"https:\/\/blog.ki.se\/nvsprefekt\/","name":"The NVS Head of department blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.ki.se\/nvsprefekt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/blog.ki.se\/nvsprefekt\/#\/schema\/person\/aa04a4e5b947f775d2eb0f1724cb0da8","name":"nvsprefekt","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/cac143d503ca7ff40f299c87a89d200149e86c68819516e19e3937c32ce182e7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cac143d503ca7ff40f299c87a89d200149e86c68819516e19e3937c32ce182e7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cac143d503ca7ff40f299c87a89d200149e86c68819516e19e3937c32ce182e7?s=96&d=mm&r=g","caption":"nvsprefekt"},"url":"https:\/\/blog.ki.se\/nvsprefekt\/author\/nvsprefekt\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/posts\/113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/users\/474"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/comments?post=113"}],"version-history":[{"count":5,"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/posts\/113\/revisions"}],"predecessor-version":[{"id":122,"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/posts\/113\/revisions\/122"}],"wp:attachment":[{"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/media?parent=113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/categories?post=113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.ki.se\/nvsprefekt\/wp-json\/wp\/v2\/tags?post=113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}